PUBLISHER: The Business Research Company | PRODUCT CODE: 1949787
PUBLISHER: The Business Research Company | PRODUCT CODE: 1949787
The Aryl hydrocarbon receptor is a protein that interacts with environmental pollutants, such as dioxins, and controls gene expression linked to immune and inflammatory responses. It is utilized for regulating various biological processes, including managing autoimmune and inflammatory disorders like psoriasis, through targeted activation or suppression.
The primary types of aryl hydrocarbon receptors include CB-993113, CDR-914K058, cinnabarinic acid, and other variants. CB-993113 is a small molecule inhibitor that acts on the CBP/p300 bromodomain and is being explored for its potential in treating cancer and other diseases by regulating gene expression. These are available through multiple channels, including direct sales, online platforms, distributors, retail pharmacies, and wholesale suppliers. They are applied in the treatment of conditions such as hepatocellular carcinoma, multiple sclerosis, obesity, and osteoporosis, among others, and are utilized by end-user industries such as pharmaceuticals, biotechnology, agriculture, environmental consultancy, and research institutions.
Tariffs have increased the cost of research grade compounds, laboratory equipment, and chemical synthesis inputs used in ahr modulator development. The impact is strongest in preclinical and early research segments, where access to specialized materials is critical. Regions such as North America and Europe have experienced higher input costs due to reliance on global research supply chains. Rising tariff related expenses have influenced research budgets, sourcing strategies, and development timelines. However, tariffs have encouraged domestic research manufacturing, local reagent production, and stronger regional innovation ecosystems over the long term.
The aryl hydrocarbon receptor market research report is one of a series of new reports from The Business Research Company that provides aryl hydrocarbon receptor market statistics, including aryl hydrocarbon receptor industry global market size, regional shares, competitors with a aryl hydrocarbon receptor market share, detailed aryl hydrocarbon receptor market segments, market trends and opportunities, and any further data you may need to thrive in the aryl hydrocarbon receptor industry. This aryl hydrocarbon receptor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The aryl hydrocarbon receptor market size has grown strongly in recent years. It will grow from $4.97 billion in 2025 to $5.34 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to advances in molecular biology, growing autoimmune disease burden, increased academic research, expansion of biotech funding, improved receptor targeting technologies.
The aryl hydrocarbon receptor market size is expected to see strong growth in the next few years. It will grow to $7.12 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growth in novel immunotherapies, expansion of precision medicine, rising investment in inflammation research, increasing clinical trials, growth in biotech startups. Major trends in the forecast period include growing research into immune modulation therapies, increasing development of selective ahr modulators, rising focus on autoimmune and inflammatory diseases, expansion of preclinical and early-stage trials, increased collaboration between pharma and biotech.
The increasing prevalence of autoimmune diseases and chronic conditions is anticipated to drive the growth of the aryl hydrocarbon receptor market in the coming years. Autoimmune diseases and chronic conditions are long-term health disorders in which the immune system malfunctions or medical issues persist over time. The rise in these diseases is attributed to genetic factors, environmental influences, lifestyle choices, gut microbiome imbalances, and improved diagnostic capabilities. Aryl hydrocarbon receptor (AHR) agonists have the ability to modulate immune responses and inflammation, providing potential therapeutic benefits for autoimmune diseases and chronic conditions by regulating T-cell differentiation and immune cell function. For example, in May 2023, research from the University of Oxford, a UK-based institution, reported that autoimmune disorders affect approximately one in ten individuals, with 13% of women and 7% of men impacted across 19 studied autoimmune diseases. Consequently, the increasing prevalence of autoimmune diseases and chronic conditions is fueling the growth of the aryl hydrocarbon receptor (AHR) agonist market.
Major companies operating in the Aryl Hydrocarbon Receptor (AhR) sector are emphasizing product innovation and formulation, including the development of novel AhR modulators, to create targeted therapies for immune-mediated and inflammatory conditions, enhance safety profiles, and broaden treatment options for patients with unmet medical needs. These modulators act on the AhR pathway to regulate immune responses, presenting opportunities for precision therapy in disorders such as graft-versus-host disease, autoimmune diseases, and chronic inflammatory conditions. For example, in May 2025, Equillium, a US-based biopharmaceutical firm, unveiled its EQ504 program, an Aryl Hydrocarbon Receptor modulator designed to target critical immune pathways for improved anti-inflammatory effects. The EQ504 program aims to provide greater selectivity and minimize off-target effects, allowing for more precise modulation of immune responses while reducing toxicity. This initiative reflects the trend toward precision immune modulation, with next-generation AhR-targeted therapies seeking to tackle complex inflammatory mechanisms and deliver innovative solutions for patients with limited treatment alternatives.
In September 2024, Organon & Co., a US-based pharmaceutical company, acquired Dermavant Sciences Ltd. for an estimated $1.2 billion. Through this acquisition, Organon seeks to enhance its presence in dermatology by incorporating Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) cream, 1%, into its portfolio. Dermavant Sciences Ltd. is a US-based company dedicated to developing novel aryl hydrocarbon receptor (AHR) agonist-based treatments for dermatological conditions.
Major companies operating in the aryl hydrocarbon receptor market are Bayer AG, Eli Lilly and Company, Organon & Co., Sigma-Aldrich Corporation, Bio-Techne Corporation, Abcam plc, R&D Systems Inc., Dermavant Sciences Inc., Cayman Chemical Company, Enzo Life Sciences Inc., Tocris Bioscience, Ikena Oncology Inc., MedChemExpress LLC, Hercules Pharmaceuticals BV, Active Biotech AB, AnTolRx Inc., Aqilion AB, Azora Therapeutics Australia Pty Ltd, Sol-Gel Technologies Ltd., Actavalon Inc.
North America was the largest region in the aryl hydrocarbon receptor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aryl hydrocarbon receptor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the aryl hydrocarbon receptor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The aryl hydrocarbon receptor market consists of sales of synthetic AHR agonists, natural AHR agonists, AHR-targeted enzyme inhibitors, and pharmaceuticals targeting AHR pathways. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Aryl Hydrocarbon Receptor Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses aryl hydrocarbon receptor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for aryl hydrocarbon receptor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The aryl hydrocarbon receptor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.